Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 4
Submit an article Journal homepage
360
Views
2
CrossRef citations to date
0
Altmetric
Letter to the Editor

Response to pembrolizumab and lenalidomide in advanced refractory mycosis fungoides

Eric FountainMD Anderson Cancer Center, Houston, TX, USACorrespondence[email protected]
,
Haleigh MistryMD Anderson Cancer Center, Houston, TX, USA
,
Preetesh JainMD Anderson Cancer Center, Houston, TX, USAORCID Iconhttps://orcid.org/0000-0003-2735-168X
ORCID Icon,
Madeleine DuvicMD Anderson Cancer Center, Houston, TX, USAORCID Iconhttp://orcid.org/0000-0002-8971-4565
ORCID Icon &
Nathan FowlerMD Anderson Cancer Center, Houston, TX, USAORCID Iconhttp://orcid.org/0000-0002-9494-1877
ORCID Icon
Pages 1079-1082 | Received 25 Jun 2018, Accepted 21 Aug 2018, Published online: 10 Oct 2018

References

  • Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768–3785.
  • Arulogun SO, Prince HM, Ng J, et al. Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation. Blood. 2008;112:3082–3087.
  • Benner MF, Jansen PM, Vermeer MH, et al. Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases. Blood. 2012;119:1643–1649.
  • Talpur R, Sui D, Gangar P, et al. Retrospective analysis of prognostic factors in 187 cases of transformed mycosis fungoides. Clin Lymphoma Myeloma Leuk. 2016;16:49–56.
  • Hughes CF, Khot A, McCormack C, et al. Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. Blood. 2015;125:71–81.
  • Virmani P, Zain J, Rosen ST, et al. Hematopoietic stem cell transplant for mycosis fungoides and sézary syndrome. Dermatol Clin. 2015;33:807–818.
  • Duvic M, Tetzlaff MT, Gangar P, et al. results of a phase ii trial of brentuximab vedotin for CD30+ cutaneous t-cell lymphoma and lymphomatoid papulosis. J Clin Oncol. 2015;33:3759–3765.
  • Martinez-Escala ME, Kuzel TM, Kaplan JB, et al. Durable responses with maintenance dose-sparing regimens of romidepsin in cutaneous t-cell lymphoma. JAMA Oncol. 2016;2:790–793.
  • Whittaker SJ, Demierre MF, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol. 2010;28:4485–4491.
  • Prince HM, Kim YH, Horwitz SM, et al. Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. Lancet. 2017;390:555–566.
  • Duvic M, Pinter-Brown LC, Foss FM, et al. Phase 1/2 study of mogamulizumab, a defucosylated anti-CCR4 antibody, in previously treated patients with cutaneous T-cell lymphoma. Blood. 2015;125:1883–1889.
  • Chong BF, Wilson AJ, Gibson HM, et al. Immune function abnormalities in peripheral blood mononuclear cell cytokine expression differentiates stages of cutaneous T-cell lymphoma/mycosis fungoides. Clin Cancer Res. 2008;14:646–653.
  • Querfeld C, Rosen ST, Guitart J, et al. Results of an open-label multicenter phase 2 trial of lenalidomide monotherapy in refractory mycosis fungoides and Sézary syndrome. Blood. 2014;123:1159–1166.
  • Lesokhin AM, Ansell SM, Armand P, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34:2698–2704.
  • Khodadoust M, Rook AH, Porcu P, et al. Pembrolizumab for treatment of relapsed/refractory mycosis fungoides and sezary syndrome: clinical efficacy in a CITN multicenter phase 2 study. Oral Abstract #181. Paper presented at: ASH 58th Annual Meeting and Exposition; 2016 Dec 3; San Diego, CA.
  • Badros A, Hyjek E, Ma N, et al. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma. Blood. 2017;130:1189–1197.
  • Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009;2:36.
  • Gorgun G, Calabrese E, Soydan E, et al. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood. 2010;116:3227–3237.
  • LeBlanc R, Hideshima T, Catley LP, et al. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood. 2004;103:1787–1790.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.